Results 121 to 130 of about 459,763 (289)
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Mock-Up Test of Cast-in-Place Tunnel Lining for TBM Method
InfrastructuresSegmental tunnel linings represent a conventional method commonly employed in tunnel boring machine (TBM) operations. However, this approach presents notable limitations, including handling challenges and the presence of numerous joints prone to leakage.
Šárka Pešková +6 more
doaj +1 more source
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris +10 more
wiley +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Orthogonally complete alternative rings
Journal of Algebra, 1989 A subset X of a reduced (i.e. without non-zero nilpotent elements) ring A is called orthogonal if \(ab=0\) for all \(a,b\in X\) (a\(\neq b)\), and is orthogonally complete if every orthogonal subset of A has a supremum in A where the order is defined: \(a\leq b\) iff \(ab=a^ 2\).
openaire +2 more sources
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
Molecular Oncology, EarlyView.PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta +10 more
wiley +1 more source
“Polymerization” of Bimerons in Quasi-Two-Dimensional Chiral Magnets with Easy-Plane Anisotropy
NanomaterialsWe re-examine the internal structure of bimerons, which are stabilized in easy-plane chiral magnets and represent coupled states of two merons with the same topological charge |1/2| but with opposite vorticity and the polarity.
Natsuki Mukai, Andrey O. Leonov
doaj +1 more source